Skip to main content

1 Result(s)

within S. El Badri Remove this filter

and

  1. Article

    Open Access

    CHARIOT: a phase I study of berzosertib with chemoradiotherapy in oesophageal and other solid cancers using time to event continual reassessment method

    Berzosertib (M6620) is a highly potent (IC50  =  19 nM) and selective, first-in-class ataxia telangiectasia-mutated and Rad3-related protein kinase (ATR) inhibitor. This trial assessed the safety, preliminary ...

    S. R. Javed, S. Lord, S. El Badri, R. Harman, J. Holmes… in British Journal of Cancer (2024)

    Download PDF (1164 KB) View Article